The Centers for Medicare and Medicaid Services (CMS) has assigned a permanent J-code, J3403, to Encelto (Neurotech Pharmaceuticals), effective October 1, 2025. The implant is approved in the United States for the treatment of adults with idiopathic Macular Telangiectasia type 2 (MacTel).

J-codes are standardized reimbursement codes that allow health care providers to bill government and commercial insurers for physician-administered therapies. Assignment of a permanent code streamlines claims processing and may facilitate broader patient access.

Encelto is the first and only US Food and Drug Administration (FDA)–approved treatment for MacTel. The therapy involves a surgically implanted capsule, about the size of a grain of rice, which contains genetically modified cells that continuously release recombinant human ciliary neurotrophic factor (CNTF) to protect retinal cells. RP